Rani Therapeutics Holdings, Inc
RANI
Positions held
Your positionsRANI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $111.29M | Enterprise value | $50.33M | Trailing P/E | — | Forward P/E | -4.17 |
| PEG | — | Price / book | 2.27 | Beta | 0.71 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -5.2% |
| Profit margin | 0.0% | ROE | -1.7% | ROA | -53.0% | Debt / equity | 0.07 |
| Current ratio | 5.31 | Free cash flow | -$8.87M | Analyst recommendation | strong_buy | Mean target | $7.20 |
| 52w high | $3.87 | 52w low | $0.45 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.7M | $1.7M | $1.5M | $0.0M | $0.0M |
| Op margin | -516.9% | -488.2% | -584.2% | — | — |
| Net income | -$7.4M | -$7.0M | -$10.3M | -$5.4M | -$6.7M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$8.8M | -$8.3M | -$8.5M | -$7.3M | -$10.5M |
- Revenue +0% vs prior quarter ($1.7M vs $1.7M).
- Operating margin compressed to -516.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.6M | $1.0M | $0.0M | $0.0M | — |
| Op margin | -2346.0% | -4824.9% | — | — | — |
| Net income | -$29.7M | -$30.0M | -$34.0M | -$30.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$38.3M | -$49.6M | -$66.1M | -$63.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
2026-09-08 · Rani Therapeutics to Participate in Upcoming September Conferences
2026-08-28 · 3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts
2026-08-16 · Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
2026-08-13 · Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
2026-08-04 · Rani Therapeutics Appoints Michelle Gilson to Board of Directors
2026-07-20 · Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns